

BIONTECH

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/ Collaborator	Milestones
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced melanoma (Adjuvant & Metastatic)					Global	Start phase 2 trial with registrational potential in 2H 2020
		BNT112	Prostate cancer					Global	
		BNT113	HPV16+ head and neck cancer ¹					Global	Start phase 2 trial with registrational potential in 2H 2020
		BNT114	Triple negative breast cancer ⁴					Global	Data update in 2H 2020
		BNT115	Ovarian cancer ¹					Global	
		BNT116	NSCLC					Global	
	iNeST (patient specific cancer antigen therapy)	RO7198457 (BNT122 ⁴)	1L melanoma with CPI ²					Genentech (global 50:50 profit/loss share)	Enrollment update in 2H 2020 ³ ; interim data update in 2021
			Multiple solid tumors						Two Phase 2 trials planned in adjuvant indications in 2H 2020
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid tumors (<i>IL-12sc</i> , <i>IL-15sushi</i> , <i>GM-CSF</i> , <i>IFNα</i>)					Sanofi (global profit/loss share)	Data update in 2H 2020 ⁵
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple solid tumors					Global	Phase 1 start in 1H 2021
		BNT142	Multiple solid tumors (<i>CD3+CLDN6</i>)					Global	Phase 1 start in 1H 2021
	RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple solid tumors (<i>Optimized IL-2</i>)					Global	Phase 1 start in 1H 2021
BNT152, BNT153		Multiple solid tumors (<i>IL-7, IL-2</i>)					Global	Phase 1 start in 1H 2021	
Cell Therapies	CAR-T Cells	BNT211	Multiple solid tumors (<i>CLDN6</i>)					Global	Phase 1/2 start in 2H 2020
		BNT212	Pancreatic, other cancers (<i>CLDN18.2</i>)					Global	
	Neoantigen-based T cell therapy	BNT221 (NEO-PTC-01)	Multiple solid tumors					Global	Phase 1 start in 2H 2020
	TCRs	To be selected	All tumors					Global	
Antibodies	Next-Gen CP ⁶ Immunomodulators	GEN1046 (BNT311)	Multiple solid tumors (<i>PD-L1×4-1BB</i>)					Genmab (global 50:50 profit/loss share)	Data update in 2H 2020
		GEN1042 (BNT312)	Multiple solid tumors (<i>CD40×4-1BB</i>)						
	Targeted Cancer Antibodies	BNT321 (MVT-5873)	Pancreatic cancer (<i>sLea</i>)					Global	
SMIM ⁷	Toll-Like Receptor Binding	BNT411	Solid tumors (<i>TLR7</i>)					Global	Phase 1 start in 2H 2020

Other

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/ Collaborator	Milestones
mRNA	Infectious Disease Immunotherapies	BNT161	Influenza					Pfizer	Start first study in 2021
		BNT162	COVID-19					Fosun Pharma (China), Pfizer (Global, except China)	Data update Phase 2/3 in Q4 2020
		To be selected	Up to 10 indications					Penn ⁸	First Phase 1 trial to start in 1H 2021
		To be selected	HIV and tuberculosis					Bill & Melinda Gates Foundation	
	Rare Disease PRT ⁹	BNT171	Not disclosed					Genevant (global 50:50 profit/loss share)	First Phase 1 trial to start in 2H 2021
		To be selected	4 more rare disease indications						

1 BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials

2 Checkpoint Inhibitor

3 Update on the ongoing study including patient enrollment number, efficacy and safety data for an interim update expected in the second half of 2021

4 BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42); BNT122 (iNeST) is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional treatment

5 As the trial is sponsored and conducted by Sanofi, the timing of data updates is not under our control and is subject to change by Sanofi

6 Checkpoint

7 Small Molecule Immunomodulators

8 We are eligible to receive worldwide licenses

9 Protein Replacement Therapy